EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Cerevel Therapeutics Holdings's enterprise value is $6,958.47 Mil.
Cerevel Therapeutics Holdings's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 was $-416.15 Mil. Therefore, Cerevel Therapeutics Holdings's EV-to-EBITDA for today is -16.72.
The historical rank and industry rank for Cerevel Therapeutics Holdings's EV-to-EBITDA or its related term are showing as below:
CERE'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -36.03 Med: 0 Max: 0
Current: -16.72
CERE's EV-to-EBITDA is ranked worse than 100% of 467
companies
in the Biotechnology industry
Industry Median: 9.63
vs CERE: -16.72
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
As of today (2024-04-16), Cerevel Therapeutics Holdings's stock price is $41.27.
Cerevel Therapeutics Holdings's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was $-2.670. Therefore, Cerevel Therapeutics Holdings's PE Ratio for today is At Loss.
The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio.
Cerevel Therapeutics Holdings EV-to-EBITDA Historical Data
The historical data trend for Cerevel Therapeutics Holdings's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* Premium members only.
Cerevel Therapeutics Holdings Annual Data
Trend
Dec19
Dec20
Dec21
Dec22
Dec23
EV-to-EBITDA
-
-11.81
-19.14
-12.89
-16.98
Cerevel Therapeutics Holdings Quarterly Data
Dec19
Mar20
Jun20
Sep20
Dec20
Mar21
Jun21
Sep21
Dec21
Mar22
Jun22
Sep22
Dec22
Mar23
Jun23
Sep23
Dec23
EV-to-EBITDA
-12.89
-8.96
-12.14
-8.32
-16.98
Competitive Comparison
For the Biotechnology subindustry, Cerevel Therapeutics Holdings's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cerevel Therapeutics Holdings EV-to-EBITDA Distribution
For the Biotechnology industry and Healthcare sector, Cerevel Therapeutics Holdings's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Cerevel Therapeutics Holdings's EV-to-EBITDA falls into.
Cerevel Therapeutics Holdings's current Enterprise Value is $6,958.47 Mil.
Cerevel Therapeutics Holdings's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-416.15 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
Cerevel Therapeutics Holdings's PE Ratio for today is calculated as:
Cerevel Therapeutics Holdings's share price for today is $41.27.
Cerevel Therapeutics Holdings's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-2.670.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.
Cerevel Therapeutics Holdings EV-to-EBITDA Related Terms
Thank you for viewing the detailed overview of Cerevel Therapeutics Holdings's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.
Cerevel Therapeutics Holdings (Cerevel Therapeutics Holdings) Business Description
Cerevel Therapeutics Holdings Inc is dedicated to unraveling the mysteries of the brain to treat neuroscience diseases. The company is tackling neuroscience diseases with a differentiated approach that combines expertise in neurocircuitry with a focus on receptor selectivity. It has a diversified pipeline comprising five clinical-stage investigational therapies and several preclinical compounds with the potential to treat a range of neuroscience diseases, including schizophrenia, epilepsy, Parkinson's disease and substance use disorder. Cerevel Therapeutics is advancing its current research and development programs while exploring new modalities through internal research efforts, external collaborations or potential acquisitions.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
CERE has been successfully added to your 